Dr. Chapple is an expert in adaptive clinical trial designs, particularly Bayesian methods. His 2019 paper “A hybrid Phase I-II/III clinical trial design allowing for dose re-optimization in Phase III” proposed a new framework for seamless drug development through the three stages of clinical trial design. This paper was recognized globally by the statistical community when it received the award for “Best Paper” from Biometrics, a top tier statistical journal.Dr. Chapple has produced many new trial designs and methods, which are accompanied with user-friendly R packages. Dr. Chapple trained under Dr. Peter Thall at MD Anderson, who is a pioneer in Bayesian adaptive trials. He later refined these skills working with cancer researchers from other institutions. Dr. Chapple’s adaptive trial designs were used to dose-find in pediatric brain tumors in a trial conducted at Harvard and the Dana Farber Cancer Center.Dr. Chapple has designed hundreds of studies and has supported many research departments at LSUHSC including: Orthopedics, OBGYN, Hematology Oncology, Dermatology, Oral Surgery, Endodontics, Cancer, Virology, Cellular Biology, Inflammation, and treatment disparities research. As a joint professor in Orthopedics, Dr. Chapple works on large scale electronic records databases which requires processing longitudinal information from patients on hospital encounters, diagnoses, procedures, prescriptions, and lab values.
